Basilea Pharmaceutica: Delivering Innovative Pharmaceuticals
About Basilea
Basilea Pharmaceutica International Ltd is a leading biopharmaceutical company established in 2000. Headquartered in Allschwil, Switzerland, the company focuses on developing and commercializing innovative pharmaceutical products to address unmet medical needs.
Products and Pipeline
Basilea's portfolio includes a range of therapies for infectious diseases, oncology, and immunology. Key products include:
- Ceftobiprole: an antibiotic for serious bacterial infections
- Lizoxanide: an antiparasitic drug
- Plerixafor: a treatment for multiple myeloma
Basilea also has a promising pipeline of investigational candidates in various stages of development.
Financial Performance
Basilea is a publicly traded company listed on the SIX Swiss Exchange. The company has a strong financial track record, with revenue growing consistently in recent years. In 2023, the company reported net sales of CHF 220 million.
Contact Information
For inquiries, you can contact Basilea Pharmaceutica International Ltd at:
Allschwil Hegenheimermattweg 167b4123 Allschwil, Switzerland
Komentar